Related Experiment Video
Updated: Apr 21, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C
Simone Susser1, Eva Herrmann2, Christian Lange1
1Medical Department 1, Goethe-University Hospital Frankfurt/Main, Frankfurt, Germany.
Interferon-lambda (IFN-L4) and IL28B gene polymorphisms predict treatment success for chronic hepatitis C. Combining these genetic markers optimizes prediction of sustained virologic response (SVR) for personalized antiviral therapies.
Area of Science:
- Genetics and Personalized Medicine
- Hepatology and Virology
- Pharmacogenomics
Background:
- IL28B gene polymorphism is a key predictor of response to interferon alfa-based therapies for chronic hepatitis C.
- A novel IFN-L4 polymorphism has been identified as a functional variant influencing IL28B expression.
- Personalizing interferon alfa therapies using combined IL28B/IFN-L4 polymorphisms can improve outcomes and resource allocation.
Purpose of the Study:
- To assess the optimization of treatment outcome prediction by combining IL28B and IFN-L4 polymorphisms.
- To evaluate the predictive value of these polymorphisms in chronic hepatitis C patients across different genotypes.
- To determine the accuracy of prediction for sustained virologic response (SVR) with various treatment regimens.
Main Methods:
- Analysis of IL28B and IFN-L4 polymorphisms in chronic HCV patients (genotypes 1, 2/3, 4) treated with PEG-IFN/ribavirin, with or without telaprevir.
- Inclusion of healthy individuals from Germany and Egypt as controls for genotype frequency comparison.
- Correlation of single nucleotide polymorphisms (SNPs) with SVR rates across different HCV genotypes and treatment combinations.
Main Results:
- Beneficial IL28B rs12979860 C/C and ss469415590 TT/TT genotypes were less frequent in HCV genotypes 1/4 infected patients compared to controls.
- Single IFN-L4 SNPs (rs12979860, rs8099917, ss469415590) correlated with SVR in HCV genotypes 1, 3, and 4, but not genotype 2.
- High accuracy (71-96%) SVR prediction was achieved using combined IL28B/IFN-L4 genotypes in patients receiving dual or triple therapies.
Conclusions:
- IFN-L4 appears to be the strongest single predictor of SVR in genotype 3 infected patients.
- Combining IFN-L4 haplotypes offers optimized SVR prediction (71-96% positive predictive value) for dual and first-generation PI triple therapies.
- Genotyping for IL28B and IFN-L4 polymorphisms can guide personalized treatment strategies for chronic hepatitis C.
More Related Videos
08:26Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
Published on: June 14, 2018
10:10Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses
Published on: November 16, 2016
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu